[Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia].
A 37-year-old woman was diagnosed with therapy-related acute promyelocytic leukemia (t-APL) in May 2006 after chemotherapy that included etoposide for ovarian cancer in November 2003. After treatment with all-trans retinoic acid in combination with chemotherapy, complete remission was attained. The patient was admitted on March 19, 2007 due to cerebral infarction and it was found that t-APL had recurred. Induction therapy with gemtuzumab ozogamicin (GO) was attempted. Molecular remission was attained without serious complication. GO is considered a promising agent to achieve molecular remission in patients with relapsed t-APL.
Shimokawa
Takayoshi
T
Department of Hematology, Nagoya Ekisaikai Hospital.
Kojima
Yumi
Y
D000328:Adult; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D005047:Etoposide / Q000009:adverse effects*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000188:drug therapy*; D012074:Remission Induction
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D000079982:Gemtuzumab